1. Progression and treatment of HER2-positive breast cancer

   • April Davoli
   • Barbara A. Hocevar
   • Thomas L. Brown

   Mini Review 20 December 2009 Pages: 611 - 623

   

2. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents

   • Terence O’Reilly
   • Paul M. J. McSheehy
   • H. A. Lane

   Original Article 27 September 2009 Pages: 625 - 639

   

3. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial

   • Joung-Soon Jang
   • Ho Yeong Lim
   • Sang Jae Lee

   Original Article 04 August 2009 Pages: 641 - 647

   

4. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

   • George Fountzilas
   • Anna Fragkoulidi
   • Marios Marselos

   Original Article 05 August 2009 Pages: 649 - 660

   

5. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients

   • Julie Fidlerova
   • Petra Kleiblova
   • Zdenek Kleibl

   Original Article 01 August 2009 Pages: 661 - 669

   

6. Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

   • Alexander M. M. Eggermont
   • Marna G. Bouwhuis
   • Christine Xu

   Original Article 21 July 2009 Pages: 671 - 677

   

7. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer

   • Gabriella Ferrandina
   • Valentina Mey
   • Mario Del Tacca

   Original Article 29 July 2009 Pages: 679 - 686

   

8. RETRACTED ARTICLE: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis

   • Nidhi Nigam
   • Jasmine George
   • Yogeshwer Shukla

   Original Article 24 July 2009 Pages: 687 - 696

   

9. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells

   • Tuba Ozbay
   • Donald L. Durden
   • Rita Nahta

   Original Article Open access 28 July 2009 Pages: 697 - 706

   

10. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

    • Jennifer P. Arbitrario
    • Brian J. Belmont
    • Pietro Taverna

    Original Article 01 August 2009 Pages: 707 - 717

    

11. Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam.

    • Hironori Iwasaki
    • Takafumi Okabe
    • Hirosuke Oku

    Original Article 23 July 2009 Pages: 719 - 726

    

12. Evaluation of the exposure equivalence of oral versus intravenous temozolomide

    • Blanca D. Diez
    • Paul Statkevich
    • Fabio H. Ottaviano

    Original Article Open access 30 July 2009 Pages: 727 - 734

    

13. Molecular determinants of folate levels after leucovorin administration in colorectal cancer

    • Sotaro Sadahiro
    • Toshiyuki Suzuki
    • Toshinori Oka

    Original Article 28 July 2009 Pages: 735 - 742

    

14. Population pharmacokinetic model of PI-88, a heparanase inhibitor

    • Susan F. Hudachek
    • S. Gail Eckhardt
    • Daniel L. Gustafson

    Original Article 25 July 2009 Pages: 743 - 753

    

15. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes

    • Alison Jones
    • Mary O’Brien
    • Véronique Trillet-Lenoir

    Original Article 09 August 2009 Pages: 755 - 763

    

16. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

    • Paul Haluska
    • Frank Worden
    • Gary D. Hammer

    Original Article 02 August 2009 Pages: 765 - 773

    

17. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy

    • Noelle K. LoConte
    • Maureen Smith
    • Kyle D. Holen

    Original Article 01 August 2009 Pages: 775 - 780

18. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial

    • Delphine Rolland
    • Vincent Ribrag
    • Catherine Thieblemont

    Clinical Trial Report 04 December 2009 Pages: 781 - 790

    

19. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

    • Michael B. Jameson
    • Danny Rischin
    • William R. Wilson

    Clinical Trial Report 10 December 2009 Pages: 791 - 801

    

20. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease

    • Tomoya Fukui
    • Sakiko Otani
    • Noriyuki Masuda

    Short Communication 25 December 2009 Pages: 803 - 806

    

21. Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer

    • Nariaki Tomiyama
    • Muneaki Hidaka
    • Chizuko Nakamura

    Short Communication 27 December 2009 Pages: 807 - 809

    

22. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy

    • P. Mathew
    • N. Tannir
    • L. Pagliaro

    Short Communication 06 January 2010 Pages: 811 - 815